Quality of survival reporting in chemotherapy and surgery trials in patients with metastatic colorectal carcinoma.

about

Quality of survival reporting in chemotherapy and surgery trials in patients with metastatic colorectal carcinoma.

Item

http://www.wikidata.org/entity/Q36384600

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Quality of survival reporting ...... tastatic colorectal carcinoma.

@ast

Quality of survival reporting ...... tastatic colorectal carcinoma.

@en

type

Item

label

Quality of survival reporting ...... tastatic colorectal carcinoma.

@ast

Quality of survival reporting ...... tastatic colorectal carcinoma.

@en

prefLabel

Quality of survival reporting ...... tastatic colorectal carcinoma.

@ast

Quality of survival reporting ...... tastatic colorectal carcinoma.

@en

P1476

Quality of survival reporting ...... tastatic colorectal carcinoma.

@en

P2093

Charles R Scoggins

http://www.w3.org/2001/XMLSchema#string

Kelly M McMasters

http://www.w3.org/2001/XMLSchema#string

Robert C G Martin

http://www.w3.org/2001/XMLSchema#string

Vedra A Augenstein

http://www.w3.org/2001/XMLSchema#string

P2860

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.

Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).

Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer.

P304

1389-1394

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.21692

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P577

2006-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7321541

http://www.w3.org/2001/XMLSchema#string

P698

16453329

http://www.w3.org/2001/XMLSchema#string